Breast Cancer Research and Treatment

, Volume 138, Issue 1, pp 325–328 | Cite as

A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians

Letter to the Editor

References

  1. 1.
    Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRefGoogle Scholar
  2. 2.
    van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21(4):589–624PubMedCrossRefGoogle Scholar
  3. 3.
    Guth U et al (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428–433PubMedCrossRefGoogle Scholar
  4. 4.
    Guth U et al (2011) Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: How often and how often does it work? Breast Cancer Res Treat 129(3):799–807PubMedCrossRefGoogle Scholar
  5. 5.
    Rae JM et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9(4):258–264PubMedCrossRefGoogle Scholar
  6. 6.
    Ishak KJ et al (2007) Meta-analysis of longitudinal studies. Clin Trials 4(5):525–539PubMedCrossRefGoogle Scholar
  7. 7.
    Klein JP et al (2007) Analyzing survival curves at a fixed point in time. Stat Med 26(24):4505–4519PubMedCrossRefGoogle Scholar
  8. 8.
    Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48Google Scholar
  9. 9.
    McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768PubMedCrossRefGoogle Scholar
  10. 10.
    Partridge AH et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562PubMedCrossRefGoogle Scholar
  11. 11.
    Kimmick G et al (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445–3451PubMedCrossRefGoogle Scholar
  12. 12.
    Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128PubMedCrossRefGoogle Scholar
  13. 13.
    Neugut AI et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29(18):2534–2542PubMedCrossRefGoogle Scholar
  14. 14.
    Nekhlyudov L et al (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689PubMedCrossRefGoogle Scholar
  15. 15.
    Huiart L, Dell’Aniello S, Suissa S (2011) Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104(10):1558–1563PubMedCrossRefGoogle Scholar
  16. 16.
    Huiart L et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946PubMedCrossRefGoogle Scholar
  17. 17.
    Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2012) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. doi:10.1097/coc.0b013e3182436ec1
  18. 18.
    Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606PubMedCrossRefGoogle Scholar
  19. 19.
    Grunfeld EA et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97–102PubMedCrossRefGoogle Scholar
  20. 20.
    Ma AM et al (2008) Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 196(4):500–504PubMedCrossRefGoogle Scholar
  21. 21.
    Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H (2009) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in earlystage breast cancer. J Clin Oncol 28(14):2423–2429Google Scholar
  22. 22.
    Ziller V et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431–436PubMedCrossRefGoogle Scholar
  23. 23.
    Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125(1):191–200PubMedCrossRefGoogle Scholar
  24. 24.
    Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 1(4):E1–E21. doi:10.5600/mmrr.001.04.a04 Google Scholar
  25. 25.
    Thompson AM et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279–287PubMedCrossRefGoogle Scholar
  26. 26.
    Wigertz A et al (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373PubMedCrossRefGoogle Scholar
  27. 27.
    Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328PubMedGoogle Scholar
  28. 28.
    Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315PubMedCrossRefGoogle Scholar
  29. 29.
    Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220PubMedCrossRefGoogle Scholar
  30. 30.
    Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRefGoogle Scholar
  31. 31.
    Owusu C et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4):549–555PubMedCrossRefGoogle Scholar
  32. 32.
    Schwartzberg LS et al (2009) Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast 18(2):78–83PubMedCrossRefGoogle Scholar
  33. 33.
    van Herk-Sukel MP et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851PubMedCrossRefGoogle Scholar
  34. 34.
    Dittmer C et al (2011) Compliance to adjuvant therapy in breast cancer patients. Eur J Gynaecol Oncol 32(3):280–282PubMedGoogle Scholar

References for Rebuttal letter

  1. 1.
    Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRefGoogle Scholar
  2. 2.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. (2012) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: a randomised trial. LancetGoogle Scholar
  3. 3.
    Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102PubMedCrossRefGoogle Scholar
  4. 4.
    Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315PubMedCrossRefGoogle Scholar
  5. 5.
    Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRefGoogle Scholar
  6. 6.
    Huiart L, Bouknik A, Rey D, Tarpin C, Cluze C, Bendiane MK, Viens P, Giorgi R (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Laetitia Huiart
    • 1
    • 2
    • 3
  • Cyril Ferdynus
    • 1
  • Roch Giorgi
    • 2
    • 3
    • 4
  1. 1.Unité de Soutien Méthodologique, CHU La Réunion—CHFGSaint-DenisFrance
  2. 2.INSERM, U912 (SESSTIM)MarseilleFrance
  3. 3.Université Aix Marseille, IRD, UMR-S912MarseilleFrance
  4. 4.Service de Santé Publique et d’Information Médicale, Hôpital de la Timone, Assistance Publique—Hôpitaux de MarseilleMarseille CedexFrance

Personalised recommendations